Associations of anemia persistency with medical expenditures in Medicare ESRD patients on dialysis

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 319-330

  Liu, Jiannong ^a   Guo, Haifeng ^a   Gilbertson, David ^a   Foley, Robert ^a,b   Collins, Allan ^a,b  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Anemia persistency; End stage renal disease; Medical costs; Structural equation modeling

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CHRONIC DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIALYSIS; DISEASE SEVERITY; DRUG COST; FOLLOW UP; HEALTH CARE COST; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MATHEMATICAL MODEL; MEDICAID; MEDICARE; OUTCOMES RESEARCH; REVIEW; STRUCTURAL EQUATION MODELING; TREATMENT OUTCOME; VASCULAR ACCESS;

EID: 77949443781     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s4856     Document Type: Review

References (21)

1. US Renal Data System. USRDS 2006 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006.
2. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis. 1997;30(4 Suppl 3):S192-S240.
3. National Kidney Foundation. K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target. Am J Kidney Dis. 2007;50:471-530.
4. Robertson HT, Haley NR, Guthrie M, Cardenas D, Eschbach JW, Adamson JW. Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients. Am J Kidney Dis. 1990;15:325-332.
5. Pickett JL, Theberge DC, Brown WS, Schweitzer SU, Nissenson AR. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis. 1999;33(6):1122-1130.
6. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53-61.
7. Harris DCH, Lawrence S, Champion JR. Low dose erythropoietin in maintenance hemodialysis patients: improvement in quality of life and reduction in true cost of hemodialysis. N Z Med J. 1991;21:693-700.
8. Stevens ME, Summerfield GP, Hall AA. Cost benefits of low dose subcutaneous erythropoietin in patients with anemia of end stage renal disease. Br Med J. 1992;304:474-477.
9. Powe NR, Griffiths RI, Watson AJ, et al. Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients. J Am Soc Nephrol. 1994;4(7):1455-1465.
10. Collins AJ, Li S, Ebben J, Ma JZ, Manning W. Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis. 2000;36(2):282-293.
11. Collins AJ, Li S, St. Peter WL, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36% to 39%. J Am Soc Nephrol. 2001;12:2465-2473.
12. Ishani A, Guo H, Gilbertson DT, et al. Time to target haemoglobin concentration (11 g/dl)-risk of hospitalization and mortality among incident dialysis patients. Nephrol Dial Transplant. 2007;22:2247-2255.
13. Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM. Identifying persons with diabetes using Medicare claims data. Am J Med Qual. 1999;14(6):270-277.
14. Kline RB. Principles and practice of Structural Equation Modeling. New York, NY: The Guilford Press; 1998.
15. Bartholomew DJ, Knott M. Latent Variable Models and Factor Analysis. 2nd ed. New York, NY: Oxford University Press; 1999.
16. Batista-Foguet JM, Coenders G, Ferragud MA. Using structural equation models to evaluate the magnitude of measurement error in blood pressure. Stat Med. 2001;20(15):2351-2368.
17. Donaldson GW. General linear contrasts on latent variable means: structural equation hypothesis tests for multivariate clinical trials. Stat Med. 2003;22(18):2893-2917.
18. Lee SY, Song XY. Bayesian analysis of structural equation models with dichotomous variables. Stat Med. 2003;22(19):3073-3088.
19. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol. 2006;1(6):1205-1210.
20. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584-590.
21. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20): 2085-2098.